- Page 1 and 2:
2011.3 INFORMATION IN ENGLISH ON JA
- Page 3 and 4:
Table of Contents CHAPTER 1 ···
- Page 5 and 6:
4.1 GMP Compliance Reviews ····
- Page 7 and 8:
TABLE 3 DATA TO BE SUBMITTED WITH A
- Page 9 and 10:
eliability of application data. Fol
- Page 11 and 12:
3) Control of household products co
- Page 13 and 14:
health care information-processing
- Page 15 and 16:
eevaluation of gastrointestinal dru
- Page 17 and 18:
contribution to drug research and d
- Page 19 and 20:
Ministry of Health, Labour, and Wel
- Page 21 and 22:
Committee on Japanese Pharmacopoeia
- Page 23 and 24:
CHAPTER 2 Pharmaceutical Laws and R
- Page 25 and 26:
11) (License standards, restriction
- Page 27 and 28:
of approvals and licenses, approval
- Page 29 and 30:
2) Classification according to hand
- Page 31 and 32:
(3) Quasi-drug marketing business l
- Page 33 and 34:
manufacturer submits an MF registra
- Page 35 and 36:
(4) On-site surveys for accreditati
- Page 37 and 38:
y testing facilities for nonclinica
- Page 39 and 40:
Implementation of Clinical Studies
- Page 41 and 42:
December 21, 2005. Based on this La
- Page 43 and 44:
Activities Encouraging Illicit Cond
- Page 45 and 46:
(7) General review conference (main
- Page 47 and 48:
diseases, a decision must be made w
- Page 49 and 50:
and use of drugs for pediatric use
- Page 51 and 52:
codevelopment group and requirement
- Page 53 and 54:
January 28, 2011 entitled “Issuan
- Page 55 and 56:
pharmaceutical excipients, physicoc
- Page 57 and 58:
application review of raw materials
- Page 59 and 60:
half of the 1980s and there were al
- Page 61 and 62:
Patent right 1 Patent right 2 Calcu
- Page 63 and 64:
Foreign manufacturer with manufactu
- Page 65 and 66:
Table. 1 List of Main Controlled Su
- Page 67 and 68:
Table. 2 Divisions of the Pharmaceu
- Page 69 and 70:
acceptance of the data is condition
- Page 71 and 72:
p) Consultations on compliance with
- Page 73 and 74:
http://www.pmda.go.jp/topics/file/
- Page 75 and 76:
Approval of Manufacturing/Marketing
- Page 77 and 78:
Summary of biopharmaceutics and ass
- Page 79 and 80:
1998 and partial revision by Office
- Page 81 and 82:
evised or established concerning ph
- Page 83 and 84:
are performed on the basis of the G
- Page 85 and 86:
Pharmaceuticals (ICH S2B) (Notifica
- Page 87 and 88:
Quality Assurance Units Chapter 3 (
- Page 89 and 90:
y made to Notification No. 813 of t
- Page 91 and 92:
international harmonization of appr
- Page 93 and 94:
clinical exploration and developmen
- Page 95 and 96:
the primary objective of exploring
- Page 97 and 98:
dose not exceeding 1/100 of the dos
- Page 99 and 100:
must be analyzed precisely and obje
- Page 101 and 102:
(21) Structure and Content of Clini
- Page 103 and 104:
approved drugs and post-marketing c
- Page 105 and 106:
specified in the ICH guidelines (IC
- Page 107 and 108:
standards for the sponsoring of cli
- Page 109 and 110:
management of clinical trials (Arti
- Page 111 and 112:
PFSB dated October 1, 2008 and Offi
- Page 113 and 114:
trial sponsors (Article 59). Howeve
- Page 115 and 116:
e judged by personnel of the qualit
- Page 117 and 118:
standards, the Minister of Health,
- Page 119 and 120:
esults thereof. * Manufacturer, etc
- Page 121 and 122:
is clear that the items relating to
- Page 123 and 124:
carries out the duties set forth be
- Page 125 and 126:
in the two countries. These mutual
- Page 127 and 128:
PMSB dated February 22, 2000), Guid
- Page 129 and 130:
Information on approval reviews for
- Page 131 and 132:
Nonclinical studies Clinical studie
- Page 133 and 134:
(Table 3) Drug classification syste
- Page 135 and 136:
(Table 4) Drug classification syste
- Page 137 and 138:
Module 2 2.3: Quality overall summa
- Page 139 and 140:
Step 5* Q1A(R2) Q1B Q1C Q1D Q1E Q2
- Page 141 and 142:
Step 5* E1 Step 4* E2A Code E2B(M)
- Page 143 and 144:
1998. Furthermore, a new guideline,
- Page 145 and 146:
supervisor, quality assurance super
- Page 147 and 148:
work is required and retention of c
- Page 149 and 150:
prepared, reported in writing and r
- Page 151 and 152:
etain these reports. [5] The safety
- Page 153 and 154:
egard to results of clinical studie
- Page 155 and 156:
surveyed, analytical method and oth
- Page 157 and 158:
marketers’ compliance surveys by
- Page 159 and 160:
approval (known or unknown). g) Ser
- Page 161 and 162: Information about adverse drug reac
- Page 163 and 164: 6.2 Periodic Safety Reports (Articl
- Page 165 and 166: Reexamination is based on submissio
- Page 167 and 168: Post-marketing surveillance (PMS) s
- Page 169 and 170: Planning of early post-marketing su
- Page 171 and 172: (MHLW) (PMDA [KIKO]) Selection of r
- Page 173 and 174: and the Role of the Regulatory Auth
- Page 175 and 176: which they are entered in package i
- Page 177 and 178: the beginning of the Precautions wh
- Page 179 and 180: 1.5 Entries for Biological Products
- Page 181 and 182: 2.2 Pharmaceutical Interview Forms
- Page 183 and 184: the basis of an order issued in cas
- Page 185 and 186: the journals of the Japan Medical A
- Page 187 and 188: Labeling requirements of excipients
- Page 189 and 190: No PMDA safety assessment team (5 t
- Page 191 and 192: CHAPTER 6 Health Insurance Programs
- Page 193 and 194: coverage was changed to 80% of medi
- Page 195 and 196: OF DRUGS LISTED IN THE NHI DRUG PRI
- Page 197 and 198: (excluding those in the JP) in the
- Page 199 and 200: 0212-(6) of the Health Policy Burea
- Page 201 and 202: 1998 Sept. 1997 5% 2% (Long listed
- Page 203 and 204: Table 9. Requirements for Applying
- Page 205 and 206: Within 60 days as a rule or 90 days
- Page 207 and 208: Index 1 15-Day reports (ADR) ......
- Page 209 and 210: Quality Standards and Government Ce
- Page 211: (MHLW) Office of New Drug III (PMDA
- Page 215 and 216: (Chapter 4) Kazuyo MARUCHI Product